

Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8⁺ T Cells

Jan Willem Kleinovink¹, Marieke F. Fransen¹, Clemens W. Löwik², and Ferry Ossendorp¹



Abstract

Photodynamic therapy (PDT) is a clinically applied tumor ablation method that reduces tumor burden and may induce T-cell responses, providing a therapeutic option for mutated tumors. In this study, we applied PDT in two mouse tumor models and assessed its effect on outgrowth of PDT-treated and distant untreated tumors. PDT of established tumors resulted in complete tumor eradication in most mice, which were then protected against tumor rechallenge. Correspondingly, the therapeutic effect was abrogated upon systemic depletion of CD8⁺ T cells, indicating PDT-induced tumor antigen cross-presentation and T-cell activation. In a double-tumor model, PDT of primary

tumors induced enhanced infiltration of untreated distant tumors by CD8⁺ T cells, which significantly delayed their outgrowth. Combination therapy of PDT and CTLA-4–blocking antibodies significantly improved therapeutic efficacy and survival of double-tumor-bearing mice. These results show that local tumor ablation by PDT induces CD8⁺ T-cell responses crucial for systemic tumor eradication, which can be further enhanced by combination with immune checkpoint blockade. This combination of two clinically applied therapies may be a treatment strategy for advanced cancer without previous knowledge of tumor-specific antigens. *Cancer Immunol Res*; 5(10); 832–8. ©2017 AACR.

Introduction

Clinically apparent cancers often evade immune eradication and progress, despite the presence of antitumor T-cell responses (1). Immune evasion of tumors can be achieved through the formation of an immunosuppressive tumor microenvironment, including chronic exposure of T cells to cognate antigen. Based on the expression of immune checkpoint molecules such as PD-1 and CTLA-4 on functionally impaired tumor-infiltrating T cells, preclinical and clinical studies using PD-1 or CTLA-4–blocking antibodies have shown impressive results (2). However, there is considerable variation in individual responsiveness to immune checkpoint blockade. Some patients show durable tumor regression, whereas others fail to respond to therapy (3–5). Combination strategies may improve clinical outcome, either by blocking multiple immune checkpoints or by combining immunotherapy with tumor-ablating therapies such as chemotherapy, radiotherapy, or photodynamic therapy (PDT; refs. 6, 7). PDT is a strongly localized and nonmutagenic method of tumor-cell killing, minimizing adverse effects of

therapy (8). PDT for cancer consists of localized activation of a light-sensitive photosensitizer by exposure of the tumor to visible light. Besides merely reducing tumor burden, the resulting massive tumor-cell death triggers strong acute inflammation involving the influx of neutrophils and macrophages (9). Dying tumor cells can serve as a source of tumor antigen and immunogenic factors able to induce or enhance tumor-specific T-cell responses, which may strongly enhance the therapeutic effect (10, 11). In a previous study, we showed that combination of PDT and specific peptide vaccination induced CD8⁺ T-cell responses against tumor antigens resulting in the clearance of both treated and distant untreated tumors (12). Therefore, the therapeutic potential of PDT may be superior in immunogenic tumor models in which tumor-specific T cells are present but unable to clear the tumor, mimicking a common clinical situation. In this study, we apply Bremachlorin-based PDT to MC38 and CT26 tumors, two mutated mouse tumors syngeneic to the C57BL/6 and BALB/c mouse strains, respectively. PDT treatment of established tumors resulted in complete tumor clearance dependent on CD8⁺ T cells, which could also control outgrowth of distant untreated tumors. In a double-tumor setting, PDT of primary tumors combined with systemic CTLA-4 blockade significantly reduced the tumor burden in both MC38 and CT26 tumor models. Our findings show the immunogenic and therapeutic potential of PDT in mutated tumors and a potent combination treatment for advanced cancer.

¹Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands. ²Department of Radiology, Erasmus Medical Center, Rotterdam, the Netherlands.

Note: Supplementary data for this article are available at Cancer Immunology Research Online (<http://cancerimmunolres.aacrjournals.org/>).

Corresponding Author: Ferry Ossendorp, LUMC, Albinusdreef 2, 2300 RC Leiden, the Netherlands. Phone: 31715263843; Fax: 31715265267; E-mail: f.a.ossendorp@lumc.nl

doi: 10.1158/2326-6066.CIR-17-0055

©2017 American Association for Cancer Research.

Materials and Methods

Mice and tumor cell lines

C57BL/6 mice were obtained from Harlan Laboratories—ENVIGO (the Netherlands), and BALB/c mice were purchased

from Charles River (France) and housed under specified pathogen-free conditions in the animal facility of the Leiden University Medical Center. All animal experimentations were approved by and according to guidelines of the Dutch Animal Ethical Committee. MC38 and CT26 cells (kindly provided by Mario Colombo) were cultured as described elsewhere (13). Cell lines were mycoplasma and MAP-tested before the start of experiments, and cultured for 2 weeks (3–5 passages) before inoculation. For tumor inoculation, 5×10^5 tumor cells in 100 μ L PBS were injected subcutaneously in the right flank or both flanks of the mice. In double-tumor experiments, the largest tumor on day 8 was designated primary tumor. Tumor volume was measured 3 times per week by caliper and calculated as length \times width \times height. Survival curves are based on the moment of sacrificing the mice upon reaching the maximally allowed tumor volume of 2,000 mm³.

PDT

Tumors were treated 8 days after inoculation at an average tumor diameter of 5 mm. PDT was performed as described previously (12). In short, Bremachlorin photosensitizer (20 mg/kg; RadaPharma International) was injected intravenously. After 6 hours, the tumors were irradiated for 1,000 seconds at 116 mW/cm² (total energy 116 J/cm²) using a 662 nm Milon Lakhta laser.

Anti-CTLA-4 antibody treatment

Antagonistic CTLA-4–blocking antibody (clone 9D9; BioXCell) was administered intraperitoneally on days 7, 10, and 14 after tumor inoculation, using 200 μ g dissolved in 200 μ L PBS per treatment.

T-cell depletion

Depleting CD8 antibody (clone 2.43) and depleting CD4 antibody (clone GK1.5) were produced in-house using hybridomas. To deplete T cells, mice received an intraperitoneal injection of 50 μ g depleting antibody the day before treatment, followed by additional injections of 50 μ g antibody when periodical screening (every 5 days from day 10 after initial injection) showed return of the targeted T-cell population in systemic blood. All control mice received similar amounts of isotype control rat immunoglobulin G in parallel.

Flow cytometry

Ex vivo tumor analysis was performed as described elsewhere (13). Tumors were harvested 6 days after PDT, incubated with Liberase TL (Roche), cut into small pieces, and mashed on 70 μ m cell strainers (BD) to create single-cell suspensions. Cells were then stained with the viability dye 7-AAD (Invitrogen) and the cell surface markers CD45.2 (clone 104; BioLegend), CD3 ϵ (clone 145-2C11; BioLegend), CD8 α (clone 53-6.7; BioLegend), CD69 (clone H1.2F3; BioLegend), and 4-1BB (clone 1AH2; BD), and measured on a LSRII cytometer (BD) analyzed with FlowJo software (Tree Star).

Statistical analysis

Statistical analysis was performed using GraphPad Prism version 6.0 software. Data are shown as the mean \pm SEM for each group, and comparison of groups was performed by two-tailed Student *t* test or Mann–Whitney *U* test

depending on normality of data distribution. Survival curves were compared using the Log-rank Mantel–Cox test. Statistical differences were considered significant at $P < 0.05$.

Results

Tumor ablation by PDT depended on CD8⁺ T cells

We applied PDT using the photosensitizer Bremachlorin to C57BL/6 mice bearing established subcutaneous MC38 tumors and followed tumor outgrowth. Whereas tumors in untreated mice grew progressively, a single PDT treatment caused strong and durable tumor regression in all mice (Fig. 1A, solid lines). In less immunogenic models, PDT was only effective when combined with specific induction of antitumor CD8⁺ T cells (12). Therefore, we analyzed whether the clearance of MC38 tumors by PDT monotherapy was mediated by CD8⁺ T cells by depleting them systemically. In the absence of CD8⁺ T cells, initial tumor regression upon PDT remained intact, but tumors eventually grew out. This suggests that tumor ablation by PDT works independently of CD8⁺ T cells, whereas CD8⁺ T cells are crucial in subsequent tumor clearance and prevention of tumor regrowth (Fig. 1A and Supplementary Fig. S1). Consequently, PDT treatment cleared MC38 tumors in the majority of mice, resulting in significantly improved long-term survival, which was fully abrogated when CD8⁺ T cells were depleted (Fig. 1B). Untreated tumors also grew faster in the absence of CD8⁺ T cells, suggesting that growth control of untreated tumors is mediated by CD8⁺ T cells. Conversely, depletion of CD4⁺ T cells resulted in slower growth of untreated tumors and enhanced clearance of PDT-treated tumors (Supplementary Fig. S1), which may suggest a suppressive role of CD4⁺ regulatory T cells. All PDT-treated tumor-free mice were protected against developing new tumors when new MC38 tumor cells were injected in the contralateral flank 50 days after tumor clearance, suggesting the formation of immunological memory (Supplementary Fig. S2). In summary, a single PDT treatment could fully eradicate established tumors involving CD8⁺ T-cell responses.

Local PDT-induced systemic T-cell responses inhibiting distant tumor growth

The induction of CD8⁺ T-cell responses and their involvement in tumor clearance suggested that T cells may circulate systemically and target untreated tumors growing at distant sites. We inoculated mice with MC38 tumor cells in both flanks and treated the largest tumor with PDT, following the outgrowth of both tumors over time. Also, in the double-tumor setting, PDT-treated tumors regressed and were cleared (Fig. 2A). Untreated tumors grew significantly slower if the contralateral tumor received PDT treatment, an effect that was completely abrogated when CD8⁺ T cells were systemically depleted (Fig. 2B). Individual tumor outgrowth curves are shown in Supplementary Fig. S3A–S3D. Local PDT caused clearance of treated tumors and delayed the growth of distant tumors, dramatically prolonging survival of double-tumor-bearing mice (Fig. 2C). Analysis of distant tumors 6 days after PDT of contralateral primary tumors showed an increased infiltration of activated CD8⁺ T cells compared with untreated mice, suggesting that CD8⁺ T cells directly mediate the abscopal effect of local PDT




Figure 1.

Tumor ablation by PDT depends on CD8⁺ T cells. Tumor outgrowth curves (A) and survival curves (B) of mice bearing subcutaneous MC38 tumors treated by PDT in the presence or absence of CD8⁺ T cells, plus corresponding control groups. PDT was given on day 8 by injection of Bremachlorin photosensitizer followed by tumor illumination 6 hours later. CD8⁺ T cells were depleted by antibodies injected periodically from day 7 until mice were sacrificed or tumor-free. Survival is defined by the time until tumor size reached the maximally allowed volume of 2,000 mm³ according to local legislation. For survival curves, the log-rank test was used to determine significance: ***, $P < 0.001$ and ****, $P < 0.0001$. Pooled data of 2 independent experiments, 13 to 15 mice per group.

(Supplementary Fig. S3E and S3F). Thus, these data indicate that local PDT triggers a CD8⁺ T-cell-dependent effect on untreated distant tumors.

Combined local PDT and systemic CTLA-4 blockade in double-tumor models

Local PDT treatment slowed down the growth of distant tumors via CD8⁺ T cells but did not fully clear them. We, therefore, analyzed whether enhancing the PDT-induced CD8⁺ T-cell response by immune checkpoint blockade would enable double-tumor eradication. We treated double MC38 tumor-bearing mice with PDT of one tumor and provided systemic CTLA-4 blockade during the treatment phase. Whereas local PDT affected the primary tumor more strongly than the untreated secondary tumor, systemic CTLA-4 blockade caused a more pronounced growth delay of the smaller secondary tumors (Fig. 3A and B). Combination treatment with PDT and CTLA-4 blockade combined the strong respective effects of each treatment on both tumors and reduced total tumor burden compared with either monotherapy (Fig. 3C). We also analyzed the combination of PDT and CTLA-4 blockade in the more aggressive CT26 tumor model in BALB/c mice. Both PDT and CTLA-4 monotherapies were less efficient in delaying the growth of primary or secondary CT26 tumors compared with their effects on MC38 tumors. However, combination treatment significantly reduced CT26 tumor burden compared with either single treatment (Fig. 3D–F). Comparison of the effects of each treatment on primary and secondary MC38 or CT26 tumors is provided in Supplementary Fig. S4. This treatment strategy provides an efficient combination of local tumor-destructive therapy with


systemic immunomodulation in two independent tumor models.

Long-term survival after combined PDT and CTLA-4 blockade depended on CD8⁺ T cells

Both PDT and CTLA-4 blockade as monotherapies significantly reduced MC38 tumor burden and increased survival time of double MC38 tumor-bearing mice (Fig. 4A). The significantly lower tumor burden after combined treatment by PDT and CTLA-4 blockade resulted in a significantly further extended survival of all mice and clearance of both tumors in 20% of the mice (Fig. 4A). A depletion experiment of CD8⁺ T cells showed that the enhanced efficacy of combined PDT and CTLA-4 blockade is dependent on the systemic presence of CD8⁺ T cells, as the combined treatment effect is fully lost in the absence of CD8⁺ T cells, reducing survival to the level of untreated mice (Fig. 4B).

Discussion


In this study, we show that PDT of mouse colon carcinoma tumors mediated strong tumor ablation and eradication by CD8⁺ T cells, which also delayed distant tumor growth. This provides evidence that local tumor ablation can lead to systemically active T-cell responses, likely by enhanced cross-presentation of tumor antigens by local dendritic cells and the immunostimulatory effects of PDT-induced cell death (10). Our data add to a growing body of evidence that local tumor destruction can delay the growth of identical tumors growing in other sites of the body, and stress the induction of systemic immune responses as the crucial

**Figure 2.**

Local PDT induces systemic T-cell responses inhibiting distant tumor growth. Primary (A) and secondary (B) tumor outgrowth curves and (C) survival curves of double MC38 tumor-bearing mice in which the primary tumor was left untreated or PDT-treated in the presence or absence of CD8⁺ T cells. PDT was given on day 8 by injection of Bremachlorin photosensitizer followed by tumor illumination 6 hours later. CD8⁺ T cells were depleted by antibodies injected periodically from day 7 until mice were sacrificed or tumor-free. Survival is defined by the time until tumor size reached the maximally allowed volume of 2,000 mm³ according to local legislation. The log-rank test was used to determine significance. Statistical significance of differences in secondary tumor volume (B) of untreated vs. PDT-treated mice was determined by *t* test (days 10 and 15) or Mann-Whitney *U* test (days 13 and 17). Statistical significance of survival differences (C) was determined by the log-rank test. n.s., not significant; *, *P* < 0.05 and ***, *P* < 0.0001. Pooled data of 6 independent experiments, 48–57 mice per group.

mechanism. These tumor-specific systemic effects of local therapy, also known as the abscopal effect, have been described in several localized ablation therapies (14, 15). The advent of modern immunomodulatory antibodies has triggered a range of protocols combining local tumor ablation with immune checkpoint blockade (16–18). A study combining local radiotherapy with immunomodulatory antibodies indicated that the enhanced therapeutic efficacy was mediated

by tumor antigen cross-presentation by dendritic cells to CD8⁺ T cells (19). Enhanced systemic efficacy of PDT combined with immune checkpoint blockade has been reported using experimental setups involving surgical resection of PDT-treated tumors or advanced nanocarrier systems (20–22). Here, we combined local PDT with systemic CTLA-4 blockade in two independent tumor models to improve the therapeutic outcome in double-tumor-bearing mice. The efficacy of

**Figure 3.**

Efficient treatment of local and distant tumors by combined local PDT and systemic CTLA-4 blockade. Tumor growth curves. Primary tumors (A), secondary tumors (B), and total tumor (C) burden for mice bearing two MC38 tumors. Primary tumors (D), secondary tumors (E), and total tumor burden (F) for mice bearing two CT26 tumors. Mice received either PDT of primary tumors on day 8, systemic CTLA-4–blocking antibody on days 7, 10, and 14, both therapies, or were left untreated. Mann-Whitney U test (MC38 model) and *t* test (CT26 model) were used to determine statistical significance of differences in total tumor burden of mice receiving PDT+αCTLA-4 combination therapy compared with PDT or αCTLA-4 monotherapy. *, $P < 0.05$ and **, $P < 0.01$. Pooled data of 2 independent experiments, 14–16 mice per group.

immunomodulatory antibodies such as CTLA-4 blockade is often largely determined by tumor size at the start of treatment. In our double-tumor model, CTLA-4 blockade indeed affected smaller secondary tumors more strongly than bigger primary tumors, whereas PDT obviously affected the PDT-treated tumor more strongly. The increased efficacy of combination therapy in our double-tumor experiments may, therefore, be explained by the combining the strengths of each individual treatment. CTLA-4 blockade specifically depletes tumor-infiltrating regulatory T cells in several tumor models, including MC38 and CT26, favoring the subsequent expansion of intratumoral effector CD8⁺ T cells (23, 24). In a preclinical study using depletion of regulatory T cells by low-dose cyclophosphamide in the context of PDT treatment, increased antitumor immune responses were observed (25). These findings suggest a suppressive role of regulatory T cells that dampen the PDT-induced T-cell responses that may further explain the superior efficacy of combined PDT and CTLA-4 blockade as described in this

study. Combination therapy of PDT and specific peptide vaccination enhances PDT-induced T-cell responses, allowing eradication of local and distant tumors (12). Combinations of PDT with specific immunotherapy allow efficient treatment of tumors of which the antigenic profile is known, such as human papillomavirus (HPV)-induced gynecological and head/neck tumors expressing known HPV antigens. Here, we introduced combination therapy of PDT and CTLA-4 blockade as a more broadly applicable therapeutic option without the need to identify the antigens expressed by the tumor. PDT is already clinically applied in the treatment of various tumors, including HPV-induced cancer, skin tumors, and gastrointestinal malignancies. CTLA-4 blockade has been approved for use in melanoma, and clinical trials for several other types of human cancer are underway, based on promising results in preclinical studies. Combinations of PDT and CTLA-4 blockade can, therefore, be smoothly introduced into clinical practice and may be applied to a wide variety of human cancer types.




Figure 4.

Long-term survival after combined PDT and CTLA-4 blockade depends on CD8⁺ T cells. **A**, Survival curves of double MC38 tumor-bearing mice receiving either PDT of primary tumors on day 8, systemic CTLA-4-blocking antibody on days 7, 10, and 14, both therapies, or left untreated. **B**, Survival curves of double MC38 tumor-bearing mice left untreated or receiving PDT+αCTLA-4 combination therapy with or without CD8⁺ T-cell depletion on day 7. Survival is defined by the time until tumor size reached the maximally allowed volume of 2,000 mm³ according to local legislation. The log-rank test was used to determine significance. **, $P < 0.01$ and ***, $P < 0.001$. Pooled data of 2 independent experiments, 14–16 mice per group.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: J.W. Kleinovink, M.F. Fransen, C.W. Löwik, F. Ossendorp

Development of methodology: J.W. Kleinovink, M.F. Fransen, F. Ossendorp

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): J.W. Kleinovink, M.F. Fransen

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.W. Kleinovink, M.F. Fransen

Writing, review, and/or revision of the manuscript: J.W. Kleinovink, M.F. Fransen, C.W. Löwik, F. Ossendorp

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.W. Kleinovink
Study supervision: F. Ossendorp

Acknowledgments

The authors would like to thank Harrie Vink, Henk Schaminée, Toon Zeegers, and Geert Haasnoot for their support.

Grant Support

J.W. Kleinovink was supported by Dutch Cancer Society (KWF) grant #UL2014-6828.

Received January 31, 2017; revised June 24, 2017; accepted August 21, 2017; published OnlineFirst August 29, 2017.

References

- Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8⁺ T cells in patients with melanoma. *J Immunol* 2005;175:6169–76.
- Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252–64.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711–23.
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–54.
- Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. *J Clin Oncol* 2015;33:1974–82.
- Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. *Front Oncol* 2014;4:385.
- Drake CG. Combination immunotherapy approaches. *Ann Oncol* 2012;23 (suppl 8):viii41–viii46.
- Ibbotson SH. Adverse effects of topical photodynamic therapy. *Photodermatol Photoimmunol Photomed* 2011;27:116–30.
- Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. Photodynamic therapy of cancer: an update. *CA Cancer J Clin* 2011;61: 250–81.
- Mroz P, Hashmi JT, Huang Y-Y, Lange N, Hamblin MR. Stimulation of anti-tumor immunity by photodynamic therapy. *Expert Rev Clin Immunol* 2011;7:75–91.
- Mroz P, Szokalska A, Wu MX, Hamblin MR, Theoret M. Photodynamic Therapy of tumors can lead to development of systemic antigen-specific immune response. Mosley RL, editor. *PLoS One* 2010;5:e15194.
- Kleinovink JW, Van Driel PB, Snoeks TJ, Prokopi N, Fransen MF, Cruz LJ, et al. Combination of photodynamic therapy and specific immunotherapy efficiently eradicates established tumors. *Clin Cancer Res* 2016; 22:1459–68.
- Kleinovink JW, Marijt KA, Schoonderwoerd MJA, van Hall T, Ossendorp F, Fransen MF. PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. *Oncoimmunology* 2017;6:e1294299.
- Bastianpillai C, Petrides N, Shah T, Guillaumier S, Ahmed HU, Arya M. Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment. *Tumor Biol* 2015;36: 9137–46.
- Formenti SC, Demaria S. Systemic effects of local radiotherapy. *Lancet Oncol* 2009;10:718–26.
- Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. *Cancer Immunol Res* 2015;3:345–55.

17. Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L, et al. Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. *Cancer Res* 2012;72:430–9.
18. Belcaid Z, Phallen JA, Zeng J, See AP, Mathios D, Gottschalk C, et al. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. *PLoS One* 2014;9:1–9.
19. Rodriguez-Ruiz ME, Rodriguez I, Garasa S, Barbes B, Solorzano JL, Perez-Gracia JL, et al. Abscopal effects of radiotherapy are enhanced by combined immunostimulatory mAbs and are dependent on CD8 T cells and cross-priming. *Cancer Res* 2016;137:canres.0549.2016.
20. Gao L, Zhang C, Gao D, Liu H, Yu X, Lai J, et al. Enhanced anti-tumor efficacy through a combination of integrin $\alpha\beta 6$ -targeted photodynamic therapy and immune checkpoint inhibition. *Theranostics* 2016;6:627–37.
21. He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum RR, et al. Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. *Nat Commun* 2016;7:12499.
22. Duan X, Chan C, Guo N, Han W, Weichselbaum RR, Lin W. Photodynamic therapy mediated by nontoxic core-shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer. *J Am Chem Soc* 2016;138:16686–95.
23. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. *J Exp Med* 2013;210:1695–710.
24. Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. *Cancer Immunol Res* 2013;1:32–42.
25. Reginato E, Mroz P, Chung H, Kawakubo M, Wolf P, Hamblin MR. Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. *Br J Cancer* 2013;109:2167–74.